Oruka Therapeutics, Inc. (HAM:HQ1) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Made bigger: about US$700.4M · US$72.5 a share · Leerink Partners +5 Dealers: Leerink Partners (co-lead), TD Cowen (co-lead), Goldman Sachs & Co. LLC (co-lead), Stifel (co-lead), Guggenheim Securities (co-lead), LifeSci Capital | Apr 28, 2026 |
| Private placement of common stock and pre-funded warrants Closed: US$180M raised · US$15 a share · Jefferies +3 Dealers: Jefferies (co-lead), TD Cowen (co-lead), Guggenheim Securities (co-lead), LifeSci Capital (co-lead) Buyers: Viking Global Investors (led the PIPE financing); Affinity Healthcare Fund; Blackstone Multi-Asset Investing; Commodore Capital; Cormorant Asset Management; Deep Track Capital; Fairmount; Great Point Partners, LLC; Palo Alto Investors, LP; Perceptive Advisors; Surveyor Capital; Venrock Healthcare Capital Partners Use of proceeds: Extend cash runway over one year past three Phase 2 readouts (ORKA-001 Phase 2a and 2b, ORKA-002 Phase 2) | Nov 12, 2025 |